chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pfizer vaccine was administered without being diluted. Tried to notify mother on 9/30/2022, no answer, Left message to call me back. Tried to call again 10/3/2022 0800, Left message to call back. 11:30 am Mom called back, states that child was fine all weekend, stated that she had a headache on Friday evening. Mom stated that she was fine rest of weekend.
Patients received the Moderna Covid 19 vaccine after temperature excursion; Patients received the Moderna Covid 19 vaccine after temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients received the Moderna Covid 19 vaccine after temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients received the Moderna Covid 19 vaccine after temperature excursion) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On 26-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. In April 2022, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients received the Moderna Covid 19 vaccine after temperature excursion). On 26-Apr-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patients received the Moderna Covid 19 vaccine after temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients received the Moderna Covid 19 vaccine after temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients received the Moderna Covid 19 vaccine after temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Reporter seems temperature excursions with her freezer in the facility where she works. It was happening for weeks since Apr-2022.  The storage condition at the time of the excursion was reported as frozen storage.  The affected batch lot numbers were reported as 065K21A and 045L21A.  The temperatures excursion range was reported as maximum 30 Fahrenheit degrees and minimum minus18.9 Fahrenheit degrees.  The vaccines suffered 2 temperature excursions since April, both of which lasted less than 1 minute.  The vials were stored frozen.  Visual inspection did not note any vaccine state change.  Treatment information was not provided.
On Sunday, March 28, 2021, the lymph node in the left armpit swelled (same arm as the injection). Monday, March 29th at red hard plump, approximately 5 inches in diameter, formed at the injection site. The lumo was slightly itchy.
Left Arm started going numb about 15 minutes after injection. The numbness spread to my  left hand shortly afterwards.  The next day numbness and tingling spread to both feet and both hands. Hands and feet were extremely cold. Blood pressure was elevated to 150 and 160s over 100s for 7 to 10 days afterwards. Same symptoms occurred after the second shot as well. I'm still experience some numbness and tingling as well as cold extremities, but not everyday.
She presented for pain to her right arm.  She notes Monday night (3/29/21) she couldn't sleep well, so she decided to lay on her right side, with her arm up and tucked beneath the pillow.  She woke up about 1-1.5 hours later with a "Charlie horse" in her bicep area, pain was so intense that she was crying/in tears.  Notes that her right hand has been colder than her left and with numbness since Monday.  Use of the right arm causes pain, such as brushing her hair.  She does have DDD, and notes some pain/issues with her right shoulder - so she's wondering if she has a pinched nerve.  At this time she is having some numbing pain near the right side of her neck.  She received COVID vaccine on 3/15/21 according to immunization registry.
Information has been received from a physician concerning a female with a history of thyroid cyst who on 17-JUN-2008 was vaccinated with the first dose of GARDASIL.  On approximately 24-JUN-2008, "a week after receiving" the vaccine, the patient developed symptoms of "receding small reactive lymph node in her lower LAC section".  Per physician patient will hold off in getting the succeeding GARDASIL.  The patient sought medical attention.  On an unspecified date, the patient recovered.  Additional information has been requested.  Additional information has been requested.
COVID-19; COVID-19; 1st dose-4th dose is Moderna vaccine, 5th dose, 6th dose is Pfizer vaccine; This is a spontaneous report received from a contactable reporter(s) (Physician). The reporter is the patient.  A 66-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 22Oct2022 as dose 5 (booster), single (Lot number: GH9702), in right arm and on 30May2023 as dose 6 (booster), single (Lot number: GJ6796) at the age of 66 years, in right arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 18Jan2021 as dose 1, single (Lot number: 025J20-2A), in right arm, on 15Feb2021 as dose 2, single (Lot number: 032L20A), in right arm, on 05Nov2021 as dose 3 (booster), single (Lot number: 051C21A), in right arm and on 07Apr2022 as dose 4 (booster), single (Lot number: 007J21-2A), in right arm for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ERYTHROMYCIN, start date: Jan2023; CLIMARA [ESTRADIOL], start date: Jan2023; VITAMIN D [VITAMIN D NOS], start date: Jan2023; CALCIUM, start date: Jan2023; FERROUS SULFATE, start date: Jan2023. Past drug history included: Dicloxacillin, reaction(s): "Known allergies: Dicloxacillin"; Betadine, reaction(s): "Known allergies: Betadine". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 22Oct2022, outcome "unknown", described as "1st dose-4th dose is Moderna vaccine, 5th dose, 6th dose is Pfizer vaccine"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: The patient took the Paxlovid treatment from 02Jul2023 to 06Jul2023.; Sender's Comments: Considering interchange of vaccine, the contributory role of company suspect drug to all the reported events Drug ineffective, Covid 19 cannot be excluded completely.,Linked Report(s) : US-PFIZER INC-202300250572 same reporter/patient, different drug/event;
Drug ineffective; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 23Sep2022 at 12:00 as dose 5 (booster), single (Lot number: As7164c), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Sulfa allergy" (unspecified if ongoing). Concomitant medication(s) included: BUPROPION, stop date: 11Mar2023. The following information was reported: COVID-19 (medically significant) with onset 2023, outcome "unknown"; DRUG INEFFECTIVE (medically significant) with onset 2023, outcome "unknown". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Treatment of Paxlovid started on 12Mar2023.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300109642 Same patient, different drug, different event;
Menstrual cramps and fatigue. I have had an IUD for nearly 10 years, so I do not have periods at all, nor do I have cramps. It was bad enough that I took ibuprofen, which I avoid and only take about once a year. Cramps subsided by the next day.
have  precipitated a cervical radiculopathy that she had in the past ;really classic and really bad; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of CONDITION AGGRAVATED (have  precipitated a cervical radiculopathy that she had in the past ;really classic and really bad) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Cervical radiculopathy (The patient had this event in the past).    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CONDITION AGGRAVATED (have  precipitated a cervical radiculopathy that she had in the past ;really classic and really bad). At the time of the report, CONDITION AGGRAVATED (have  precipitated a cervical radiculopathy that she had in the past ;really classic and really bad) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not reported. Treatment medication was not reported. Within hours of getting the vaccine, it seems to have precipitated a cervical radiculopathy that she had in the past, really classic and really bad.; Sender's Comments: Very limited information regarding these events has been provided at this time.  Further information has been requested.
Pt vaccinated with MMR/DTP/OPV experienced fever 103, generalized rash, Lt knee arthralgia/arthritis, flare up of eczema, abscess at injection.
Pt developed a red rash. Denied taking any medication for it. Rash resolved on its own in 1 week.
This spontaneous report was received from a nurse referring to a male patient of unknown age. Information regarding the patient's concurrent conditions and medical history was not provided. On an unspecified dates, the patient was vaccinated with 3 complete series of unspecified hepatitis b vaccine (manufacturer unknown) (lot #, route and dosage information were not provided) at unspecified facilities. Information regarding the patient's concomitant medication was not provided. The nurse reported that after the administration of the unspecified hepatitis b vaccine (manufacturer unknown) was administered, then the patient had titers drawn which also exhibited results that suggest the patient did not seroconvert. The patient's outcome was unknown at the time of reporting. The causal relationship between unspecified hepatitis b vaccine (manufacturer unknown) and the aforementioned event was not provided. This is one of 2 reports concerning the same patient. Additional information has been requested.
Blurred and spotty vision, headache- suffered an eye stroke to my (R) eye .  Blind now. ER visit, MRI, CT Scan within a couple of hours.  Visit to eye Dr and (2) retina specialists. All told me this is not reversible and no treatment will return my vision in my (R) eye.
Progressive shortness of breath and fever. Patient is fully vaccinated with Covid-19 Pfizer vaccine with positive SARS COV-19 PCR test.
After receiving the last vaccine Varicella, patient had what appeared to be a seizure - symptoms observed were slight loss of consciousness, slight muscle stiffing, and slight muscle jerking with lasted for less than 1 minute. Patient was then conscious and speaking, verbalizing nausea and sleepiness. Patient was alert and oriented by verbalize his name and date of birth, and location.  Patient was always in the presence of RN until ambulance arrival and patient was not observed to have had any other events. Epinephrine was on standby if needed, but was not administered.
Throat tightening, Benadryl po 50mg, resolution of symptoms after 20 mins
Terrible flu after firs vaccine dose; Sore arm after first vaccine dose; Weakness after first vaccine dose; Chills after first vaccine dose; Headache after first vaccine dose; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA (Terrible flu after firs vaccine dose), PAIN IN EXTREMITY (Sore arm after first vaccine dose), ASTHENIA (Weakness after first vaccine dose), CHILLS (Chills after first vaccine dose) and HEADACHE (Headache after first vaccine dose) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M30A) for COVID-19 vaccination.     Concurrent medical conditions included Mitral valve prolapse since 2017, Cholesterol, Blood pressure and Heart rate. Concomitant products included AMLODIPINE for Blood pressure management, ATORVASTATIN CALCIUM (LIPITOR) for Cholesterol, METOPROLOL for Pulse rate.    On 30-Jan-2021 at 4:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In January 2021, the patient experienced INFLUENZA (Terrible flu after firs vaccine dose), PAIN IN EXTREMITY (Sore arm after first vaccine dose), ASTHENIA (Weakness after first vaccine dose), CHILLS (Chills after first vaccine dose) and HEADACHE (Headache after first vaccine dose). At the time of the report, INFLUENZA (Terrible flu after firs vaccine dose) had resolved and PAIN IN EXTREMITY (Sore arm after first vaccine dose), ASTHENIA (Weakness after first vaccine dose), CHILLS (Chills after first vaccine dose) and HEADACHE (Headache after first vaccine dose) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-078143 (Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 24-May-2021: Patient demographic details were updated, relevant medical history was updated, concomitant medications were added.; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-078143:Case for dose 2
On day 7 post vaccine noticed redness, swelling and itching at vaccine site. On day 8 woke up with swelling and redness had spread, are became hard, warm to touch, I was seen at an urgent care facility and prescribed Keflex, prednisone and advised to take Benadryl and use hydrocortisone cream. Day 9  swelling as firmness began to decrease however the redness ?rash? did not. Day 10 (today) swelling and firmness almost completely  resolved however the redness ?rash? continues to slowly spread.
Arm soreness at injection site and tiredness starting about 12 hours after injection. Arm soreness is a little better today (day after injection), but still feeling quite tired.
Pt recvd MMR 3JUL91 fever during wk sz 12JUL91;
-Fatigue, headache, fever, dizziness, burning sensation in head 4/9/2021 ~2AM-6PM  -Fatigue 4/9/2021-4/20/21 -Fatigue, dizziness, fever, headache, dry eyes, shortness of breath 4/17/2021 5PM-12AM -Heart palpitations, fatigue, dizziness, fever, headache, dry eyes, shortness of breath 4/18/2021 3PM-4/19/2021 12AM (was hospitalized) -Resting heart-rate upon arrival to hospital was ~105
This is a spontaneous report from a contactable nurse and from a contactable physician. A 17-year-old male patient received TRUMENBA; (NDC number 0005010001; lot M68769, expiry date Apr2017) intramuscular, in left deltoid, on 19Jul2016, at 16:30, at 0.5 mg single, for immunisation. No other vaccines were given on the same date or within four weeks. The patient medical history was not reported. There were no concomitant medications. Few minutes after vaccination, on 19Jul2016, the patient experienced fever, chills, headache and rigors, all resolved on 19Jul2016. The patient was treated with ibuprofen. The events did not require an emergency room or doctor visit. The physician considered the vaccine had a causal effect to the adverse events. Follow-up (20Sep2016): New information from a contactable Physician included: causality assessment. Follow-up attempts are completed. No further information is expected.
This spontaneous report as received from a other health professional refers to a patients of unknown age and gender. On 27-JUL-2017, the patients were inadvertently vaccinated with improperly stored doses of M-M-R II for prophylaxis. Concomitant therapies included sterile diluent (MERCK STERILE DILUENT). No adverse effects reported.
Not feeling well; Loss of the taste; This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (Loss of the taste) and VACCINATION COMPLICATION (Not feeling well) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included LOSARTAN, HCTZ, METOPROLOL and AMLODIPINE for an unknown indication.    On 06-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Mar-2021, the patient experienced AGEUSIA (Loss of the taste). On an unknown date, the patient experienced VACCINATION COMPLICATION (Not feeling well). On 09-Mar-2021, AGEUSIA (Loss of the taste) had resolved. At the time of the report, VACCINATION COMPLICATION (Not feeling well) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Mar-2021, SARS-CoV-2 test: negative (Negative) Tested Negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       On 06-Mar-2021, the patient received their vaccine and since then they were not feeling well. The patient reported of having loss of the taste, but they were not having any other symptoms at all.  On 09-Mar-2021, the patient reported that they got tested for COVID and it came back negative, and also reported that their taste came back on 09-Mar-2021.  No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 09-Mar-2021: Follow-up was received on 10-Mar-2021 and contains significant information. Added the lab data. Added concomitant medications. Updated the event date and outcome of the event.
redness near site of inj, swelling used cold compact to relieve the rash;the same day of inj started to exp cold & flu-like sx;sl fever, h/a, sore throat, coughing;sx lasted for 8wk;
painful; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 28 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 02Mar2021 11:40 (Lot number: EN6198) at the age of 28 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN (non-serious) with onset Mar2021, outcome "unknown", described as "painful". No follow-up attempts are possible. No further information is expected.
Pt reports the same night as her vaccination (which was her second dose of COVID vaccine) she threw up all night long, experienced fatigue, sweats, chills, hot flashes, HAs, brain fog, severe dizziness, diarrhea, coughing, congestion, THROAT SWELLING, AND DIFFICULTY SWALLOWING. No SOB or tongue or lip swelling. She says that her symptoms have been improving over the last 4 days, but that her throat swelling is still present. She had a negative exam and SpO2 95%. Advised her to avoid any COVID vaccines in the future unless she has seen an allergist and they have cleared her to receive subsequent COVID vaccines.  Prescribed her Prednisone 40mg Once daily x 5 days for suspected allergic reaction.   OF INTERESTING NOTE: PT REPORTED THIS AS HER SECOND DOSE OF THE VACCINE, BUT UPON FURTHER RESEARCH, ACCORDING TO THE SYSTEM , THE DOSE SHE REC'D ON 6/10/21 WAS HER 4TH DOSE OF PFIZER COVID VACCINE. THAT IS NOT A TYPO. SHE HAS RECORDS FOR 4 DIFFERENT VACCINATIONS OF THE PFIZER COVID VACCINE THAT DO NOT SEEM TO BE DUPLICATED INFORMATION.
This spontaneous report was received from a registered nurse and refers to a 55 year old female patient with allergy to unspecified ACTIFED. The patient had no pertinent medical history and did not take any concomitant therapies. On 14-MAR-2018, she was vaccinated with a dose of ZOSTAVAX injection, subcutaneously, in an unspecified arm, lot # N012492, expiration date 17-MAR-2018 (exact dose was not reported) for shingles prevention, which was reconstituted with sterile diluent subcutaneously (strength, dose, frequency, lot # and expiration date were not provided). On 16-MAR-2018, the patient developed a red, swollen and pus-filled area at injection site. She sought medical attention and on an unknown date in March 2018 was admitted to the hospital and diagnosed with cellulitis on 17-MAR-2018. There were no lab diagnostics or studies performed. At the time of the report, the patient remained in the hospital and was receiving treatment with vancomycin, intravenously and ceftriaxone, intravenously. The outcome of the event was reported as recovering. The relatedness between the event and the suspect therapies was not reported.
She has a bad sore throat, congestion, and is super tired; She has a bad sore throat, congestion, and is super tired; She has a bad sore throat, congestion, and is super tired; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 17 year-old female patient received bnt162b2 (BNT162B2), administration date 09May2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose of covid vaccine), for COVID-19 immunization. The following information was reported: OROPHARYNGEAL PAIN (non-serious), NASAL CONGESTION (non-serious), FATIGUE (non-serious), outcome "unknown" and all described as "She has a bad sore throat, congestion, and is super tired".  Additional information: Reporter wanted to know if they were to get a covid test for patient to go to school, reporter was asking if there was a chance the vaccine could cause a positive result.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
A physician reported that a 9 month old male received his third dose of Rota Shield and on 9/3/99 developed acute gastroenteritis with dehydration. Stool cultures were positive for both rotavirus antigens and campylobacter jejuni. Additional information received from the physician on 11/1/99 indicated that the infant who was experiencing vomiting, diarrhea and abdominal pain received his third dose of Rota Shield on 4/8/99. On 4/3/99, the infant developed acute gastroenteritis with dehydration. Complete blood count and blood cultures were obtained; however results were not provided. The infant recovered.
pt recvd flu vax 26OCT93 & 28OCT93 exp hives; pt treated in ER w/Adrenalin inject; also treated w/DPH;
On 10/26/11 patient received HIGH DOSE flu vaccine through her local pharmacy with 2hrs developed coughing/wheezing headache, swallowing difficulty & chills on way to event dinner stopped at pharmacy to ask for advice. They recommended BENADRYL. Her 101.1 F temp went down & symptoms dissipated within the hour. When she returned home called an EMT friend who recommended TYLENOL. Pt went to bed & symptoms absent on AM.
Initial case was received from a physician on 01 October 2009. The physician, who is also the patient, reported two additional patients who experienced similar events following vaccination with FLUZONE. No identifiers were reported for the other two patients, and lot number for those patients was unknown. A male patient experienced pain and paresthesia after receiving a right arm injection of FLUZONE No Preservative 2009-2010 (lot number U3253CA) on 17 September 2009. Two days post-vaccination, on 19 September 2009, he developed paresthesia and pain in the right side of his body, from his armpit to his lower abdomen. At the time of the report, the events were still ongoing. According to the reporter, the other two patients experienced similar reactions. Documents held by sender: None.